<DOC>
	<DOCNO>NCT00024531</DOCNO>
	<brief_summary>The purpose study assess clinical benefit Lipitor , cholesterol-lowering drug , treatment Alzheimer 's disease .</brief_summary>
	<brief_title>Lipitor Treatment Alzheimer 's Disease</brief_title>
	<detailed_description>This study phase II , placebo control , double-blind , one year trial investigate effect HmG-CoA reductase inhibitor atorvastatin calcium treatment person possible probable Alzheimer 's disease . Subjects may continue take stable dos Aricept Exelon . Following enrollment , participant make visit study center every three month blood test neuropsychological testing .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Prior participation study , prospective study individual must sign informed consent form . Diagnosis probable possible Alzheimer 's disease accord NINDSADRDA DSMIV criterion . Not actively participate another clinical drug trial . MMSE range 1228 entry . Hachinski Modified Ischemic score &lt; =4 . Accompanied appropriate caregiver aid administration medication make assessment . Good general health evidence physical , neurological clinical laboratory examination . Education level &gt; = 9th grade equivalent . Fluent English language . Reliable caregiver . Able complete neuropsychological test . Ambulatory . On stable dos medication treatment nonexcluded medical condition four week prior screen . Able participate schedule evaluation . Geriatric Depression Scale &lt; = 20 . Not exceed 400 IU Vitamin E 30 day . For patient currently take donepezil , must remain stable dose least three month . Individuals take stable dos cholinesterase inhibitor include , study subject may initiate use cholinesterase inhibitor entrance trial . Individuals sex 50 year age eligible . Exclusion criterion : Significant neurological psychiatric disease Alzheimer 's disease . Patients know suspected Parkinsons 's disease dementia Lewy body . Significant systemic illness ( include uncontrolled hypertension ) organ failure . History mental illness within one year history significant untreated cardiac thromboembolic vascular disease ( arrythmias , unstable angina , CVA , deep venous thrombosis , pulmonary embolus ) . Current chronic use anticholinergic medication ( antihistamine , Artane Cogentin ) . Stable dos anxiolytic , sedative , hypnotic , antipsychotic SSRI antidepressant acceptable . The use antipsychotic tricyclic antidepressant must review prior entry . Diagnosis major depression accord DSMIV criterion last two year . Allergies atorvastatin HMG CoA reductase inhibitor . Pregnant woman . History head injury . On cholesterol lower drug time enrollment . History significant liver disease elevate transaminase . Cholesterol level low 90 mg % initial screening</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Alzheimer disease</keyword>
	<keyword>Cholesterol-lowering drug</keyword>
</DOC>